At the 44th Annual J.P. Morgan Healthcare Conference, AstraZeneca’s CFO Aradhana Sarin delivered the company’s strategic overview alongside EVP of Oncology Dave Fredrickson during the Q&A session. Sarin emphasized AZ’s commitment to expanding its R&D pipeline, noting that six oncology candidates are expected to enter late-stage clinical trials by the end of 2024. Fredrickson reaffirmed the company’s goal to file three new oncology applications with global regulatory agencies over the next 18 months, underscoring AstraZeneca’s focus on novel treatments in lung and hematological cancers.

AstraZeneca has agreed to acquire Boston-based Modella AI, a specialist in machine learning platforms for drug discovery. The deal—announced on Tuesday—will integrate Modella’s predictive modeling algorithms into AZ’s existing research infrastructure, potentially reducing early-stage candidate screening time by up to 40%. The transaction, structured as an all-cash acquisition, is expected to close in Q2 2026 and will bolster AstraZeneca’s capabilities in de novo drug design and in silico toxicity profiling. Management projects that leveraging Modella’s technology could shave 12 to 18 months off the average oncology development timeline, reinforcing AZ’s target of maintaining a five-year average pipeline entry rate above industry norms.